NEW YORK (GenomeWeb) – Biocept today announced a collaboration with Baylor College of Medicine to develop blood-based tests using Biocept's circulating tumor cell and circulating tumor DNA assay platforms.

Specifically, the partners aim to detect mutations in the estrogen receptor gene (ESR1) in order to guide treatment for women with breast cancer, and hope to develop assays to identify the emergence of mutations that confer resistance to endocrine therapies like Tamoxifen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.